This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

STENTYS Revenues For The First 9 Months Of 2013 Up 32% Over Prior Year

STENTYS (FR0010949404 – STNT), a medical technology company commercializing the world’s first and only Self-Apposing ® stent to treat Acute Myocardial Infarction (AMI), today announced its revenues for third-quarter 2013 and 9-months through September 30, 2013.

  • Trends in quarterly and 9-month 2013 revenues*
               
  9 months Quarterly - 3 months
€ thousands

9 months 2013

     

9 months 2012

     

% change

Q3 2013

      Q3 2012      

% change

Revenues 2,406.6       1,823.2       +32.0% 768.0       673.6       +14.0%

* Data reviewed by statutory auditors

 

Revenues for the third quarter of 2013 totaled €768.0 thousand, up 14% compared to the third quarter of 2012. The substitution of paclitaxel by compounds of the “limus” family, deemed more efficient, on all coronary drug-eluting stents on the market may currently slow down the STENTYS paclitaxel-eluting stent’s entry into new accounts and has yielded a more moderate growth rate this quarter. The first clinical results from the STENTYS Sirolimus-eluting stent (“limus” family) will be presented on October 29, and its commercialization outside of the United States is expected after CE Mark approval by the end of 2014.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs